Basile Edward M

SEC source: 0001193125-26-236908 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,788

F1 · shares: Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001193125-25-260849 · ownership.xml · derivative · entry 3

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,142 shares

Expires 2026-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 6, 2024.

F3 · price: The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F2 · derivative.exercise_date: The option is fully vested.

SEC source: 0001193125-25-260849 · ownership.xml · nonDerivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,866

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 6, 2024.

SEC source: 0001193125-25-260849 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,008

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 6, 2024.

SEC source: 0000950170-25-103110 · ownership.xml · derivative · entry 3

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,142

Underlying: Common Stock · 4,143 shares

Expires 2026-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F1 · derivative.exercise_date: The option is fully vested.

SEC source: 0000950170-25-103110 · ownership.xml · nonDerivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,866

SEC source: 0000950170-25-103110 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-079022 · ownership.xml · derivative · entry 3

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,285

Underlying: Common Stock · 5,000 shares

Expires 2026-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F1 · derivative.exercise_date: The option is fully vested.

SEC source: 0000950170-25-079022 · ownership.xml · nonDerivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,866

SEC source: 0000950170-25-079022 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,866

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-077227 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,866

F1 · shares: Consists of 2,134 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000950170-25-070568 · ownership.xml · derivative · entry 3

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,285

Underlying: Common Stock · 6,000 shares

Expires 2026-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F1 · derivative.exercise_date: The option is fully vested.

SEC source: 0000950170-25-070568 · ownership.xml · nonDerivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 732

SEC source: 0000950170-25-070568 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-123425 · ownership.xml · derivative · entry 4

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,750 shares

Expires 2032-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F4 · derivative.exercise_date: The option is fully vested.

SEC source: 0000950170-24-123425 · ownership.xml · nonDerivative · entry 3

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 732

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $84.00 to $84.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-123425 · ownership.xml · nonDerivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,186

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $82.91 to $83.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-123425 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

SEC source: 0000950170-24-094079 · ownership.xml · derivative · entry 6

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,750

Underlying: Common Stock · 6,750 shares

Expires 2032-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F6 · derivative.exercise_date: The option is fully vested.

SEC source: 0000950170-24-094079 · ownership.xml · nonDerivative · entry 5

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 732

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $151.80 to $152.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-094079 · ownership.xml · nonDerivative · entry 4

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,269

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $150.50 to $151.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-094079 · ownership.xml · nonDerivative · entry 3

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,269

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $149.21 to $150.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-094079 · ownership.xml · nonDerivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,652

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $147.76 to $148.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-094079 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

SEC source: 0000950170-24-070709 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 732

SEC source: 0000950170-24-065406 · ownership.xml · derivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,154

Underlying: Common Stock · 1,154 shares

Expires 2034-05-23

F2 · derivative.exercise_date: The option vests in full on the earlier of May 23, 2025 or the date of the 2025 annual meeting of the stockholders of the Issuer, subject to continued service.

SEC source: 0000950170-24-065406 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,925

F1 · shares: Consists of 732 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000950170-24-055798 · ownership.xml · nonDerivative · entry 5

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,193

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $132.00 to $132.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-055798 · ownership.xml · nonDerivative · entry 4

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,009

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $131.13 to $131.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-055798 · ownership.xml · nonDerivative · entry 3

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,109

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $130.00 to $130.775, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-055798 · ownership.xml · nonDerivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,994

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $129.00 to $129.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-055798 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,220

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $127.89 to $128.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-012810 · ownership.xml · nonDerivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,350

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $86.735 to $87.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · balance_after: Includes 1,193 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000950170-24-012810 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,734

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $85.74 to $86.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-23-024878 · ownership.xml · derivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,916

Underlying: Common Stock · 1,916 shares

Expires 2033-05-25

F2 · derivative.exercise_date: The option vests in full on the earlier of May 25, 2024 or the date of the 2024 annual meeting of the stockholders of the Issuer, subject to continued service.

SEC source: 0000950170-23-024878 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,507

F1 · shares: Includes 1,193 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000899243-23-006755 · doc4.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,314

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $80.00 to $80.43, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-23-005192 · ownership.xml · nonDerivative · entry 3

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,814

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $79.25 to $79.50, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-23-005192 · ownership.xml · nonDerivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,814

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $78.00 to $78.50, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-23-005192 · ownership.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,314

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $76.00 to $76.54, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-22-021192 · doc4.xml · derivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2032-06-01

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant, June 1, 2023, or the date of the following annual meeting of shareholders of the Company.

SEC source: 0000899243-21-021349 · doc4.xml · derivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2031-05-27

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant, May 27, 2022, or the date of the following annual meeting of shareholders of the Company.

SEC source: 0000899243-20-015428 · doc4.xml · derivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,934

Underlying: Common Stock · 15,934 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant, June 4, 2021, or the date of the following annual meeting of shareholders of the Company.

SEC source: 0000899243-19-012290 · doc4.xml · derivative · entry 5

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,285

Underlying: Common Stock · 19,285 shares

Expires 2026-02-16

F2 · kind: The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F2 · shares: The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F2 · price: The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F3 · derivative.exercise_date: The option is fully vested.

SEC source: 0000899243-19-012290 · doc4.xml · derivative · entry 4

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,285 shares

Expires 2026-02-16

F2 · kind: The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F2 · shares: The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F2 · price: The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F3 · derivative.exercise_date: The option is fully vested.

SEC source: 0000899243-19-012290 · doc4.xml · derivative · entry 3

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,314 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Preferred Stock reported herein is preferred stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer (the "Conversion"). The Preferred Stock has no expiration date.

F1 · kind: The Preferred Stock reported herein is preferred stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer (the "Conversion"). The Preferred Stock has no expiration date.

F1 · price: The Preferred Stock reported herein is preferred stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer (the "Conversion"). The Preferred Stock has no expiration date.

F1 · derivative.exercise_date: The Preferred Stock reported herein is preferred stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer (the "Conversion"). The Preferred Stock has no expiration date.

F1 · derivative.expiration_date: The Preferred Stock reported herein is preferred stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer (the "Conversion"). The Preferred Stock has no expiration date.

SEC source: 0000899243-19-012290 · doc4.xml · nonDerivative · entry 2

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,814

SEC source: 0000899243-19-012290 · doc4.xml · nonDerivative · entry 1

Basile Edward M · CIK 0001773661 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Preferred Stock reported herein is preferred stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer (the "Conversion"). The Preferred Stock has no expiration date.

F1 · price: The Preferred Stock reported herein is preferred stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), such preferred stock of TransMedics, Inc. was converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. were convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. were converted into shares of common stock of the Issuer (the "Conversion"). The Preferred Stock has no expiration date.